Lidocaine Kade

Lidocaine, the active ingredient in Lidocaine Kade, is a local anesthetic presented as a rectal formulation for use in patients requiring rectal anesthesia. It provides local anesthesia for rectal procedures and helps relieve rectal pain.

GNH USA supplies Lidocaine Kade as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocaine Kade is a local anesthetic used in the gastrointestinal tract to provide targeted pain control.

- Rectal procedures: provides local anesthesia to facilitate minor surgical or diagnostic interventions. - Rectal pain: relieves discomfort associated with conditions such as hemorrhoids or proctitis. - Anal fissure: reduces pain during the healing phase.

Lidocaine Kade may cause adverse reactions at the site of administration or systemically.

Common Side Effects: - Mild burning or stinging at the application site. - Localized itching or erythema. - Transient numbness extending slightly beyond the treated area. - Light‑headedness or dizziness. - Mild headache. - Nausea.

Serious or Rare Side Effects: - Central nervous system toxicity (e.g., seizures, confusion). - Cardiovascular effects such as arrhythmias or hypotension. - Severe allergic reaction (anaphylaxis, angioedema). - Methemoglobinemia. - Respiratory depression. - Persistent numbness or motor weakness.

When using Lidocaine Kade, consider the following safety measures.

- Assess patient history: verify no known allergy to amide‑type local anesthetics. - Use lowest effective dose: limit systemic absorption and reduce toxicity risk. - Avoid concurrent use with other sodium‑channel blockers: may potentiate cardiac effects. - Monitor for signs of toxicity: especially in patients with hepatic impairment or low body weight. - Store at room temperature: keep in the original container, protect from moisture and light.

Lidocaine Kade can interact with other medicines; awareness of the interaction level is important.

Major Interactions (Avoid): - Class I antiarrhythmic drugs (e.g., quinidine, procainamide): increased risk of cardiac toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise systemic lidocaine concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: potential additive CNS depression. - General anesthetics (e.g., propofol, sevoflurane): enhanced depressant effects on the central nervous system. - Diuretics: may alter plasma protein binding, affecting lidocaine levels.